BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
HIV infection
,
Liver
,
Avian flu virus
,
Fluoxetine
,
rs6983267
,
LEP
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
ataxia spinocerebellar
Summary
General Info
Curated Studies
Most Correlated Studies
OMIM - Ataxia
Neurons from iPSCs generated from dermal fibroblasts/PBMCs of spinocerebellar ataxia 2 and 3 patient
OMIM - Galloway-Mowat syndrome
OMIM - Spinocerebellar Ataxias
Mouse Phenotypes - Degenerative disease of the CNS
Explore Curated Studies Results
Literature
Most Relevant Literature
Myelinating Glia: Potential Therapeutic Targets in Polyglutamine Spinocerebellar Ataxias.
Rating scales and biomarkers for CAG-repeat spinocerebellar ataxias: Implications for therapy develo…
Spinocerebellar ataxia clinical trials: opportunities and challenges.
Composite autonomic severity scoring in spinocerebellar ataxia type 1 and 2.
Single-Tube Screen for Rapid Detection of Repeat Expansions in Seven Common Spinocerebellar Ataxias.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Dalfampridine and Gait in Spinocerebellar Ataxias
Identification of Biomarkers in Spinocerebellar Ataxia 3
Study of CAD-1883 for Spinocerebellar Ataxia
Measuring Neurological Impairment and Functional Visual Assessment In Spinocerebellar Ataxias
Efficacy Of Oral Trehalose In Spinocerebellar Ataxia 3
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ